Edition:
United States

Profile: Coherus BioSciences Inc (CHRS.A)

CHRS.A on American Stock Exchange

20.35USD
24 May 2019
Change (% chg)

$0.08 (+0.39%)
Prev Close
$20.27
Open
$20.39
Day's High
$20.39
Day's Low
$19.98
Volume
9,657
Avg. Vol
1,435
52-wk High
$20.68
52-wk Low
$8.40

Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351.

CHS-1701 (Pegfilgrastim (Neulasta) Biosimilar Candidate)

The Company's CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Pegfilgrastim (Neulasta), the reference product for CHS-1701, is a PEGylated form of the recombinant human G-CSF analog, filgrastim. Neulasta is indicated as a treatment to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with an incidence of febrile neutropenia.

CHS-5217 (Bevacizumab (Avastin) Biosimilar Candidate)

The Company's Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that stimulates angiogenesis, which is the formation of blood vessels. In turn, the formation of new blood vessels may contribute to promote the growth of certain solid tissues, including solid tumors. Bevacizumab is used as a combination use with standard chemotherapy for metastatic colon cancer. It is also indicated for certain lung cancers, renal cancers, ovarian cancers and glioblastoma.

CHS-0214 (Etanercept (Enbrel) Biosimilar Candidate)

The Company's Etanercept (Enbrel) is the reference product for CHS-0214, which is a complex fusion protein that combines the protein for tumor necrosis factor receptor 2 (TNFR-2), to another protein (called IgG1 Fc), which enables the fusion protein to attach to cells in the body. The TNFR-2 portion of the fusion protein binds to soluble and cell bound tumor necrosis factors alpha and beta (TNF-a and TNF- b), and inhibits TNF-a and TNF-b from binding to cell surface proteins that recognize them. Etanercept (Enbrel) treats these diseases by inhibiting TNF-a, thus inhibiting the inflammatory cytokine cascade, which is a sequence of events in the body, caused by cytokines, leading to inflammation in a tissue or organ. Enbrel is indicated for treatment of rheumatoid arthritis; juvenile idiopathic arthritis; psoriatic arthritis; ankylosing spondylitis, and psoriasis.

CHS-1420 (Adalimumab (Humira) Biosimilar Candidate)

The Company's Adalimumab (Humira) is the reference product or originator for CHS-1420, is a monoclonal antibody that can bind to a substance in the body known as TNF, thereby inhibiting the known effect of this substance as a potent mediator of inflammation. Humira provides a therapeutic benefit for treatment of various inflammatory diseases characterized by increased production of TNF in the body. Humira can also bind to receptors on white blood cells, which may lessen the ability of the body's immune system to fight infections. Humira is indicated for the therapies, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and psoriasis.

CHS-3351 (Ranibizumab (Lucentis) Biosimilar Candidate)

Lucentis is a monoclonal antibody fragment (Fab) created from the mouse antibody as bevacizumab and produced through a microbial culture. It is an anti-angiogenic, which is indicated to treat age-related wet macular degeneration (AMD). Ranibizumab blocks angiogenesis by inhibiting VEGF-A.

The Company competes with Amgen Inc., Sandoz International GmbH, Apotex Inc., Pfizer, Inc., Mylan N.V., Teva Pharmaceutical Industries, Ltd., Samsung Bioepis Co Ltd. and LG Chem, Ltd.

Company Address

Coherus BioSciences Inc

333 Twin Dolphin Dr Ste 600
REDWOOD CITY   CA   94065-1442
P: +1650.6493530
F: +1302.6555049

Company Web Links